Familial hemophagocytic lymphohistiocytosis (FHLH) is an autosomal recessive disease with features similar to those of the murine motheaten phenotype resulting from mutations of protein tyrosine phosphatase SHP-1. This has raised the possibility that defects in SHP-1 or SHP-1-regulated signaling molecules may be present in FHLH. In this study, we examined SHP-1 protein and transcript in the peripheral blood mononuclear cells (PBMC) of an FHLH family. Our results show that the FHLH patient and the parents express comparable levels of a single SHP-1 protein and that the SHP-1 cDNA clone from the patient contains no mutation in the coding region. Interestingly, a reduced association of SHP-1 with the Jak family kinase Tyk2 was detected in the patient and the defect appears to have been inherited from one of the parents. This reduced SHP-1/Tyk2 association is likely due to a defect in Tyk2 or in cellular factors regulating Tyk2, because we found no abnormalities in SHP-1 or in SHP-1 association with the other Jak kinases. These data demonstrate that the SHP-1 gene is intact in FHLH and that the defect in some cases with this disease may involve signaling molecules regulated by SHP-1.
Introduction
Familial hemophagocytic lymphohistiocytosis (FHLH) is a rare, fatal, autosomal recessive disease in infants and young children. 1 Since the original report in 1952, 2 more than 200 similar patients have been documented under various terms, including familial histiocytic reticulosis, 2 generalized lymphohistiocytic infiltration, 3 familial erythophagocytic lymphohistiocytosis, 4 lymphohistiocytose familiale, 5 familial lymphohistiocytosis 6 and familial histocytosis. 7 This disease is usually noted in the first years of life and progresses rapidly, corresponding to that of a highly aggressive neoplastic disorder. Several therapeutic strategies, including antibiotics, steroids, chemotherapy and irradiation, have failed to achieve long-term remission. 1, 8 The disease is usually fatal within a few months of presentation.
The etiology and the pathogenesis of FHLH are poorly understood at present. 8 However, it has been noticed that FHLH and the murine motheaten disease share a number of clinical and histologic features, including hematosplenomegaly, anemia, organ infiltration of histiocytes and lymphocytes, erythrophagocytosis, monocyte hyperactivity and impaired natural killer activity. 1, 9 Since the motheaten disease is associated with loss of functional hematopoietic cell phosphatase (SHP-1) due to mutations in the SHP-1 gene, 9 ,10 the clinical and histologic similarities between FHLH and the motheaten disease suggest a potential association of FHLH with abnormalities in SHP-1. SHP-1 11 is a cytoplasmic protein tyrosine phosphatase predominantly expressed in cells of the hematopoietic system 12, 13 and is also termed PTP1C, 14 SHPTP1, 15 SHP. 16 It has two srchomology 2 (SH2) domains at the amino region and a PTPase domain at the carboxyl terminal region. Previous studies indicate that SHP-1 functions by associating via its SH2 domains with specific phosphotyrosine sites 17, 18 in membrane receptors. This association leads to the activation of SHP-1 PTPase 19, 20 and the down-regulation of signaling by the dephosphorylation of substrates. A number of membrane molecules have been found to associate with SHP-1 via its SH2 domains, including receptors of hematopoietic growth factors and cytokines, [21] [22] [23] [24] [25] subunits of the B cell antigen receptors [26] [27] [28] [29] and the inhibitory receptor of natural killer cells. 30 The functional significance of these associations is underscored by the increased signaling from these membrane molecules in motheaten hematopoietic cells which lack functional SHP-1. 24, 28, [31] [32] [33] [34] It is believed that the increased signaling due to loss of the negative regulatory SHP-1 leads to hyperproliferation and organ infiltration of hematopoietic cells in these mice.
While few SHP-1 substrates have been identified, several lines of evidence indicate that SHP-1 dephosphorylates the Jak family kinases (Jak1, Jak2, Tyk2 and Jak3) which are coupled to the receptors of hematopoietic growth factors and cytokines. 35 It has been shown that a mutant of the Epo receptor (EpoR) lacking phosphotyrosine sites recognized by the SHP-1 SH2 domains induces prolonged Jak2 hyperphosphorylation and cell hyperproliferation, 25 indicating that SHP-1 is recruited to the receptor complex to dephosphorylate Jak2. Moreover, Jak kinases in macrophages from motheaten mice were found to be hyperphosphorylated following IFN␣/␤ treatment. 24 Our recent study demonstrates that SHP-1 directly binds to the Jak family kinases via a region in its N-terminus independently of SH2/phosphotyrosine interactions. 36 As this interaction leads to SHP-1 activation and the dephosphorylation of Jak kinases, it may be a critical factor required for specific and efficient dephosphorylation of SHP-1 substrates. Because the Jak kinases play critical roles in signal transduction of many hematopoietic growth factors and cytokines, 35, 37 defects in SHP-1/Jak interactions may affect SHP-1 dephosphorylation of these substrates and cause hematopoietic disorders. Interestingly, we have recently shown that GM-CSF induces only a modest Jak2 hyperphosphorylation in motheaten macrophages which contain multiple markedly hyperphosphorylated proteins. 34 This suggests that those hyperphosphorylated proteins are major SHP-1 substrates and that the role of SHP-1 in regulating Jak phosphorylation may be complicated.
In the present study, we examined SHP-1 and its interactions with the Jak kinases in the peripheral blood mononuclear cells (PBMC) from members of an FHLH family. Our data show that the protein levels, phosphatase activities and cDNA sequences of SHP-1 in these individuals are comparable to those of normal controls, demonstrating that FHLH is not associated with an intrinsic defect in SHP-1. Interestingly, the association of Tyk2, but not the other Jak family kinases, with SHP-1 is markedly reduced in the patient and one of the parents. Our results indicate a potential defect in the Tyk2 kinase or in cellular factors regulating Tyk2 that affects its interaction with SHP-1 and may contribute to pathogenesis of FHLH.
Materials and methods

Patient and patient family
The kindred involved in this study had six members (Figure 1 ). The patient was the fourth child of the family. An older child was previously deceased due to FHLH. The other two siblings and the parents are healthy. Diagnosis was established based on typical clinical symptoms, laboratory findings and family history. Peripheral blood samples were collected from the patient and the parents. The patient subsequently underwent bone marrow transplantation, developed acute graft-versushost disease (GVHD) and died during this study. Peripheral blood from three healthy volunteers (one male and two females) were also studied.
Cells, cell culture, transient transfection
Peripheral blood mononuclear cells (PBMC) were isolated by centrifugation on a density gradient (Histopaque-1077; Sigma, St Louis, MO, USA), washed three times in phosphatebuffered saline (PBS) and stored as cell pellets at −80°C.
Cos-7 cells were grown in DMEM medium supplemented with 10% FCS and transiently transfected with the expression constructs using a DEAE-dextran method. 38 The transfected cells were harvested by lysing in cold lysis buffer.
Isolation and characterization of SHP-1 and Tyk2 cDNA clones from PBMC of the FHLH family Poly A+ RNA was isolated from PBMC pellets of the FHLH patient using a QuickPrep mRNA purification kit (Pharmacia, Piscataway, NJ, USA) and reverse-transcribed into cDNA using a Superscript reamplification kit (GibcoBRL, Gaithersburg, MD, USA). SHP-1 cDNA fragments were derived from the reverse-transcribed cDNA by PCR (95°C, 1 min; 55°C, 1 min; 72°C, 2 min; for 36 cycles) using a set of oligonucleotide primers (P1, gaattcctctccggaagcccccagg; P2, ctgaattcaggttgtgagtctgtc) that flank the coding region of SHP-1 ( Figure 3a) . The cDNA fragments were digested with EcoRI, gel purified and cloned into the Bluescript vector. A SHP-1 cDNA clone of the patient was randomly selected for sequencing analysis 39 with a panel of 20 oligonucleotide primers that distribute within the coding region at approximately 200 bp distance/primer.
For isolation of Tyk2 cDNA clones from the PBMC of the patient's parents, similar procedures were followed using two sets of oligonucleotide primers (P1, gaattcagcatgcctctgcgccactgg; P2, cagtggctcccgcggcctgtc; P3, gacaggccgcgggagccactg; P4 ggaattcagcacacgctgaacactga). The Tyk2 cDNA fragments were digested with EcoRI/SstII, ligated to form full-length Tyk2 cDNA and inserted into the PRK5 vector for expression assays.
Reagents
Wild-type SHP-1 and the SHP-1 mutant cDNAs have been described. 36 The wild-type human Tyk2 cDNA was a gift from Dr George Stark, The Cleveland Clinic Foundation, Cleveland, OH, USA. The cDNA clones were inserted into the eukaryotic cell expression vector pRK5 or pXM as indicated.
The antibodies against SHP-1, Tyk2, Jak1, Jak2 and Jak3 have been reported previously. 36 The monoclonal antibody (4G10) specific for phosphotyrosine was purchased from UBI.
Immunoprecipitation and Western blotting 15 Cells and cell pellets were lysed in cold lysis buffer (50 M Tris, pH 7.4, 50 mM NaCl, 0.5% sodium deoxycholate, 0.2 mM Na 3 VO 4 , 20 mM NaF, 1% NP-40, 2 mM PMSF, 20 g/ml of aprotinin and 10% glycerol). The lysates were clarified by centrifuging for 20 min at 10 000 g at 4°C. Antisera were added to cell lysates and incubated at 4°C for 60 min with gentle agitation. Immune complexes were collected with protein A Sepharose 4B (Pharmacia) at 4°C for 30 min, washed gently in cold lysis buffer and analyzed by SDS-PAGE. For Western blotting, protein samples separated on SDS-PAGE gels were blotted on to nitrocellulose membrane (Schleicher & Schuell, Keene, NH, USA). The membranes were then blocked with 5% milk in washing buffer (10 mM Tris, pH 7.4, 150 mM NaCl, 0.1% Tween-20) for 2 h, incubated with rabbit polyclonal antibodies (1:5000 dilution of whole serum) or with the mouse monoclonal anti-phosphotyrosine antibody 4G10 (1 g/ml, UBI) for 2 h, washed for 1 h, incubated with a secondary antibody for 1 h and washed for another hour. Specific antibody signals were detected using an enhanced chemiluminescence kit (ECL, Amersham, Arlington Heights, IL, USA).
Results
PBMC of FHLH patients express normal levels of functional SHP-1 phosphatase with no mutation in its cDNA coding region
The motheaten mutations are point mutations in splicing acceptor/donor sites of the SHP-1 gene. The mutations cause deletions or insertions in SHP-1 transcript and premature translation termination, resulting in loss of SHP-1 protein expression or the expression of two forms of mutant SHP-1 proteins with sizes (66 and 71 kDa) different from the wildtype protein (68 kDa).
To determine whether motheaten mutations occur in FHLH patients, we examined the expression of SHP-1 protein in peripheral blood mononuclear cells of the FHLH patient and her healthy parents (Figure 1 ). We detected a single SHP-1 protein about 68 kDa, with comparable expression levels in these samples (Figure 2, lanes 1-6) . The SHP-1 protein immunoprecipitated from the PBMC samples was tyrosine phosphorylated and associated with phosphotyrosine proteins of 48, 32 and 30 kDa (Figure 2, lanes 8, 10 and 12) , consistent with previous findings in hematopoietic cell lines. 40 However, there were no marked differences in these samples in terms of the FHLH kindred. Family relationships are shown; affected subjects, unaffected subjects, living unsampled subjects and deceased subjects are indicated by filled symbols, unfilled symbols, dotted symbols and diagonal lines, respectively. Peripheral blood samples were collected from the parents (M1 and F1) and the patient (D1) who died during this study.
phosphorylation contents of SHP-1 or the SHP-1-associated proteins.
To determine whether SHP-1 in the FHLH patient is mutated despite the apparently normal SHP-1 protein migration, we amplified the coding region of SHP-1 cDNA from the PBMC of the patient by PCR (Figure 3a) . Consistent with our detection of a single SHP-1 protein, the PCR reaction PBMC of the FHLH family members express the wild-type SHP-1 protein. Cell lysates were prepared from PBMC of the FHLH patient (D1) and the parents (F1 and M1). SHP-1 proteins were immunoprecipitated from the lysates. The immunocomplexes and the lysates were analyzed in a 7.5% SDS-PAGE gel which can separate the wild-type and the motheaten mutants of SHP-1 proteins. 9, 34 The protein samples were then transferred to a membrane and detected with antibodies as indicated. The positions of protein size markers, SHP-1 and SHP-1-associated phosphoproteins (p48, p32 and p30) are indicated.
produced a single SHP-1 cDNA fragment of 1.8 kb (Figure 3b ). Sequencing analysis of the cDNA fragment revealed that the coding region sequence is identical to the previously reported human SHP-1 cDNA sequence 13 (data not shown), indicating that the SHP-1 protein of the patient did not have point mutations. In support of this, we found that immunoprecipitated SHP-1 from the patient and the parents had comparable PTPase activities in in vitro PTPase assays (data not shown).
Detection of reduced Tyk2/SHP-1 association in the FHLH patient and one of the parents Our recent study demonstrated that SHP-1 associates via its Nterminal region with Jak kinases. To determine whether such associations are defective in FHLH, we immunoprecipitated SHP-1 from PBMC of the patient and the parents, and probed the immunocomplexes with antibodies against the Jak kinases. Consistent with our previous reports, 36, 41 Tyk2 was detected in the SHP-1 immunocomplexes from the father (Figure 4a , lane 2). However, the levels of Tyk2 in the SHP-1 immunocomplexes from the patient and the mother were markedly reduced, representing approximately 5-10% of the father's. In contrast, similar amounts of Jak3 were detected in these SHP-1 immunocomplexes (Figure 4a, lower panel) . We also detected comparable levels of Jak1 and Jak2 in the SHP-1 immunocomplexes from these individuals (data not shown). A similar reduction of SHP-1 in the immunocomplexes of Tyk2 from the patient and the mother was also detected (data not shown). When the association of Tyk2 with SHP-1 in the PBMC of three healthy volunteers was studied, we found that the amounts of Tyk2 detected in SHP-1 immunocomplexes from such samples were similar (Figure 4b) , suggesting that the reduced Tyk2 association in the FHLH family is unlikely to be a random event. Consistent with this, comparable levels of Tyk2 were also detected in the SHP-1 immunocomplexes from PBMC samples of five additional individuals (data not shown). Status of Tyk2/SHP-1 interaction in the unaffected siblings of the FHLH kindred has not been determined as samples of the siblings were not available.
The Tyk2 encoded by cDNAs from the patient's parents show comparable association with the SHP-1/N mutant when co-expressed in Cos-7 cells
The reduced association of Tyk2, but not other Jak kinases, with SHP-1 in the FHLH patient cells suggested an intrinsic defect in Tyk2 or related molecules affecting its interactions with the phosphatase. This appears to have been inherited from the parent in whose cells a similar reduction of SHP-1/Tyk2 association was also detected.
To determine whether the potential intrinsic defect in Tyk2 is a characteristic independent of the cellular environment, we examined the interactions of Tyk2 proteins from both of the parents with SHP-1 in Cos-7 cells in transient transfection assays. Tyk2 cDNA fragments were derived from both of the parents by PCR and ligated to generate cDNA clones encoding full length Tyk2 protein (Figure 5a and b) , which were co-expressed with the SHP-1/N mutant in Cos-7 cells. The mutant has Jak-binding activity but contains point mutations inactivating the SHP-1 SH2 domains to prevent its association with phosphotyrosine receptors (Figure 5c ). 36 We detected Tyk2 protein from both parents in the anti-SHP-1/N immunocomplexes in the transfected cells (Figure 5d, lanes 3 and 4) . The amount of Tyk2 from the parent M1, whose PBMC showed reduced Tyk2/SHP-1 association, was smaller than that of the F1 Tyk2 (compare lane 4 to lane 3 of Figure 5d , upper panel). However, there was a proportionally smaller amount of SHP-1/N mutant in the immunocomplex (lane 4 of Figure 5d , middle panel). These results indicated a comparable association of Tyk2 proteins of both parents with the SHP-1 mutant, demonstrating that the differential association of SHP-1/Tyk2 in the PBMC of the parents could not be reproduced when the SHP-1/Tyk2 molecules were co-expressed in Cos-7 cells. Consistent with this, we detected comparable amounts of SHP-1/N protein in the immunocomplexes of Tyk2 from F1 and M1 (data not shown). This suggests the involvement of additional cellular factors in the reduced Tyk2/SHP-1 association. The association of SHP-1 with the Tyk2 cloned from the patient has not been determined. Since the patient and the affected parent (M1) showed a similar defect in Tyk2/SHP-1 association, it is expected that the patient Tyk2 will behave like that of the affected parent in its association with SHP-1 in similar transfection experiments.
Discussion
The clinical and pathological similarities between FHLH and the motheaten disease suggest that they originate through similar genetic defects and mechanisms. Recent discovery 9,10,42 that mutations in the SHP-1 gene correlate with the expression of the motheaten phenotype prompted us to determine whether similar mutations occur in an FHLH family. The motheaten mutations cause the expression of a truncated protein of 102 amino acids (the me mutation) or two catalytically inactive mutants of 67 and 71 kDa (the mev mutation). 9 Our results demonstrate that the SHP-1 genes in the FHLH family members contain no motheaten type of mutations since they express comparable levels of a single SHP-1 protein of 68 kDa as expected for the wild-type SHP-1. The lack of motheaten type of mutations in FHLH was also confirmed by sequencing of the coding region of an SHP-1 cDNA clone from the FHLH patient. It is consistent with our finding of single SHP-1 protein band in three additional FHLH patients (data not shown). Our results further demonstrate that the 68 kDa SHP-1 protein of the patient also contains no other types of mutations that affect its function because the SHP-1 cDNA isolated from the patient encodes a wild-type SHP-1 protein. Consistent with this, we detected comparable PTPase activities and phosphoproteins in the SHP-1 immunocomplexes from the members of the FHLH family. These results together indicate that there are no mutations in the SHP-1 gene in the FHLH patient and that SHP-1 mutation is not involved in the pathogenesis of the FHLH patient. Similar results were obtained by another group who analyzed and sequenced SHP-1 cDNA from FHLH patients (Dr RJ Matthews, personal communication).
In the absence of SHP-1 mutation, our finding of a reduced association of Tyk2, but not the other Jak kinases, with SHP-1 in the FHLH patient indicates a potential defect intrinsic in the Tyk2 molecule or in cellular factors regulating Tyk2 that affects its interactions with the phosphatase. Since dephosphorylation and inactivation of Tyk2 by SHP-1 may depend on intermolecular interactions, 36 the reduced Tyk2 association with SHP-1 may lead to increased Tyk2 activity and enhanced cellular responses that depend on the Tyk2 kinase for signal transduction. Given the functional involvement of Tyk2 in the signal transduction of multiple hematopoietic growth factors/cytokines, a hyperactive Tyk2 is not inconsistent with the hyperproliferation of hematopoietic cells that is characteristic of FHLH. While our preliminary study showed that Tyk2 from the three members of the FHLH family had similar phosphotyrosine content (our unpublished data), this result should be interpreted with caution as Tyk2 contains multiple potential phosphotyrosine sites. Their differential phosphorylation and their regulation by the phosphatase may not be readily reflected by the phosphotyrosine content of the whole protein.
Determination of the activities of Tyk2 and Tyk2-related signaling pathways in FHLH cells will help to reveal the functional consequences of the reduced Tyk2/SHP-1 association. The requirement of fresh cell samples which are not readily available limits such effort.
The nature of the putative Tyk2 defect responsible for the reduced Tyk2/SHP-1 association is not clear. Our recent studies demonstrate that the N-terminal region of SHP-1 specifically binds to all of the members of the Jak family kinases but not the src or c-fes kinases. This suggests that Jak-binding activity of SHP-1 recognizes a sequence motif conserved uniquely in the Jak kinases, which has not been clearly defined. It is possible that the putative Tyk2 defect is caused by mutations that affect the motif in the Tyk2 molecule of the patient and thus reduces Tyk2 association with SHP-1. Our current effort to map the SHP-1-binding motif in the Jak kinases will provide critical information allowing us to detect the mutations by determining putative mutations in FHLH patients. Alternatively, the Tyk2 defect may be the result of an aberrant post-translational modification of the motif, which will be more difficult to define. Moreover, it is likely that the reduced Tyk2/SHP-1 interaction involves additional cellular factors since it could not be detected outside of the original cellular environment in transfection assays ( Figure 5 ).
The detection of reduced Tyk2/SHP-1 association in the patient and one of the parents indicates that it is passed from the parent to the patient, consistent with the inherent nature of the disease. This also indicates that the reduced Tyk2/SHP-1 association is not the only pathogenic factor in FHLH because the affected parent appears healthy. The recessive nature of the genetic disease suggests that the patient may have inherited another defect from the other parent which is required and complements the putative Tyk2 abnormality in FHLH pathogenesis. This defect could be in molecules that function cooperatively with Tyk2. A number of such molecules are known, including membrane receptors, kinases and STATs that are functionally and physically coupled to Tyk2. 35, 37 Defects in the Jak family kinases are known to be associated with a number of diseases. Mutations of Jak3 have been identified in human autosomal severe combined immune deficiency (SCID) with normal ␥c chain. 43, 44 Mutations of the Jak homologue encoded by the Drosophila hopscotch locus cause development abnormalities. 45 Interestingly, a mutation that activates the Jak homologue at Tum L allele causes a leukemia-like disease in flies. [46] [47] [48] Our finding of reduced Tyk2/SHP-1 association in an FHLH family implicates a potential Tyk2 defect in this lethal human hematopoietic disease. Further studies to characterize the potential Tyk2 defect and to examine Tyk2/SHP-1 interactions in additional FHLH families will help to define its role in the pathogenesis of FHLH and allow us to assess its potential involvement in other aggressive neoplastic disorders of the hematopoietic system in the future.
